Beschreibung
Atlas of Rheumatoid Arthritis is a high-quality educational initiative, written by leaders in the field of rheumatology, containing a collection of approximately 150 relevant images, with extended descriptive captions and a comprehensive bibliography. The Atlas of Rheumatoid Arthritis will provide clinicians with a visual guide to rheumatoid arthritis, focusing on assessment, diagnosis and treatment, including newer research into the signalling pathways involved in the pathogenesis of RA, before focusing on the treatment of RA. Rheumatoid arthritis (RA) is the most common and most serious of the inflammatory arthritic disorders, and it dominates clinical rheumatological practice. Effective, early treatment is vital as this can slow the course of the disease and reduce joint damage. RA is usually treated using disease-modifying anti-rheumatic drugs (DMARDs), most commonly methotrexate. The newest treatments target the disease-causing immune elements specifically and directly.
Autorenportrait
Professor Paul Emery is the Arthritis Research UK Professor of Rheumatology and Director of
the Leeds Institute of Rheumatic and Musculoskeletal Medicine and the Director of the Leeds
Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust in Leeds, United
Kingdom. Professor Emery was the President of the European League Against Rheumatism
(EULAR) from 20092011 and has served on the editorial boards major rheumatology journals
including Rheumatology, Arthritis and Rheumatism, Annals of the Rheumatic Diseases, Clinical
and Experimental Rheumatology, and Clinical Rheumatology. He was the inaugural President of
International Extremity MRI Society (ISEMIR) and is a National Institute for Health Research
(NIHR) Senior Investigator. Professor Emery is a recipient of the Roche Biennial Award for
Clinical Rheumatology; the Rheumatology Hospital Doctor of the Year Award; the EULAR
Prize for outstanding contribution to rheumatology research; and the Carol Nachman Prize
for outstanding rheumatology research. Professor Emerys research interests center around the
immunopathogenesis and immunotherapy of rheumatoid arthritis, spondyloarthritis, and connective
tissue diseases. He has a special interest in the factors leading to persistent inflammation
and has published over 950 peer-reviewed articles in this area.
is the Arthritis Research UK Professor of Rheumatology and Directorof
the Leeds Institute of Rheumatic and Musculoskeletal Medicine and the Director of the Leeds
Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust in Leeds, United
Kingdom. Professor Emery was the President of the European League Against Rheumatism
(EULAR) from 20092011 and has served on the editorial boards major rheumatology journals
including Rheumatology, Arthritis and Rheumatism, Annals of the Rheumatic Diseases, Clinical
and Experimental Rheumatology, and Clinical Rheumatology. He was the inaugural President of
International Extremity MRI Society (ISEMIR) and is a National Institute for Health Research
(NIHR) Senior Investigator. Professor Emery is a recipient of the Roche Biennial Award for
Clinical Rheumatology; the Rheumatology Hospital Doctor of the Year Award; the EULAR
Prize for outstanding contribution to rheumatology research; and the Carol Nachman Prize
for outstanding rheumatology research. Professor Emerys research interests center around the
immunopathogenesis and immunotherapy of rheumatoid arthritis, spondyloarthritis, and connective
tissue diseases. He has a special interest in the factors leading to persistent inflammation
and has published over 950 peer-reviewed articles in this area.
Inhalt
Classification of rheumatoid arthritis.- Pre-rheumatoid arthritis.- Early rheumatoid arthritis.- Established rheumatoid arthritis.- Remission and rheumatoid arthritis.- Magnetic resonance imaging in rheumatoid arthritis.- Ultrasound imaging in rheumatoid arthritis.- Dual energy X-ray absorptiometry in rheumatoid arthritis.- Methotrexate.- Immunotherapy.- Rituximab.- Novel therapies in rheumatoid arthritis: small molecules.
Informationen zu E-Books
„E-Book“ steht für digitales Buch. Um diese Art von Büchern lesen zu können wird entweder eine spezielle Software für Computer, Tablets und Smartphones oder ein E-Book Reader benötigt. Da viele verschiedene Formate (Dateien) für E-Books existieren, gilt es dabei, einiges zu beachten.
Von uns werden digitale Bücher in drei Formaten ausgeliefert. Die Formate sind EPUB mit DRM (Digital Rights Management), EPUB ohne DRM und PDF. Bei den Formaten PDF und EPUB ohne DRM müssen Sie lediglich prüfen, ob Ihr E-Book Reader kompatibel ist. Wenn ein Format mit DRM genutzt wird, besteht zusätzlich die Notwendigkeit, dass Sie einen kostenlosen Adobe® Digital Editions Account besitzen. Wenn Sie ein E-Book, das Adobe® Digital Editions benötigt herunterladen, erhalten Sie eine ASCM-Datei, die zu Digital Editions hinzugefügt und mit Ihrem Account verknüpft werden muss. Einige E-Book Reader (zum Beispiel PocketBook Touch) unterstützen auch das direkte Eingeben der Login-Daten des Adobe Accounts – somit können diese ASCM-Dateien direkt auf das betreffende Gerät kopiert werden.
Da E-Books nur für eine begrenzte Zeit – in der Regel 6 Monate – herunterladbar sind, sollten Sie stets eine Sicherheitskopie auf einem Dauerspeicher (Festplatte, USB-Stick oder CD) vorsehen. Auch ist die Menge der Downloads auf maximal 5 begrenzt.
